MBI extends Mallinckrodt's FS069 rights

Molecular Biosystems of San Diego has extended Mallinckrodt Medical's

rights to its FS069 ultrasound contrast agent to Europe, Russia,

Africa, and India. In exchange for the new rights, Mallinckrodt

of St. Louis will pay MBI fees of up to $12.9 million, plus 40%

of product sales for royalties and manufacturing. The companies

filed a premarket approval application for U.S. marketing of FS069,

a second-generation contrast agent, earlier this year. They plan

to file for European approval in early 1997.